> top > docs > PMC:1189074 > spans > 13070-13778 > annotations

PMC:1189074 / 13070-13778 JSONTXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

Id Subject Object Predicate Lexical cue
T3078 204-221 NN denotes decenoylcarnitine
T3077 198-203 NN denotes serum
T3076 195-197 IN denotes of
T3075 222-229 JJ denotes evident
T3074 179-180 HYPH denotes -
T3073 180-184 JJ denotes fold
T3072 175-177 IN denotes to
T3071 173-174 HYPH denotes -
T3070 178-179 CD denotes 6
T3069 172-173 CD denotes 5
T3068 185-194 NN denotes elevation
T3067 170-171 DT denotes a
T3066 166-169 VBD denotes had
T3065 159-160 SYM denotes −
T3064 158-159 HYPH denotes /
T3063 157-158 SYM denotes −
T3062 161-165 NNS denotes mice
T3061 153-157 NN denotes MCAD
T3060 149-152 CC denotes but
T3059 147-149 , denotes ,
T3058 141-142 SYM denotes −
T3057 140-141 HYPH denotes /
T3056 139-140 SYM denotes −
T3055 135-139 NN denotes MCAD
T3054 131-134 CC denotes and
T3053 129-130 SYM denotes +
T3052 128-129 HYPH denotes /
T3051 127-128 SYM denotes +
T3050 143-147 NNS denotes mice
T3049 123-127 NN denotes MCAD
T3048 115-122 IN denotes between
T3047 90-99 NN denotes carnitine
T3046 84-89 NN denotes serum
T3045 100-114 NNS denotes concentrations
T3044 78-83 JJ denotes total
T3043 75-77 IN denotes in
T3042 51-62 JJ denotes significant
T3041 63-74 NNS denotes differences
T3040 48-50 DT denotes no
T3039 32-33 SYM denotes −
T3038 31-32 HYPH denotes /
T3037 30-31 SYM denotes −
T3036 26-30 NN denotes MCAD
T3035 22-25 CC denotes and
T3034 20-21 SYM denotes +
T3033 19-20 HYPH denotes /
T3032 18-19 SYM denotes +
T3031 34-38 NNS denotes mice
T3030 14-18 NN denotes MCAD
T3029 11-13 IN denotes of
T3028 39-47 VBD denotes revealed
T3027 0-10 NN denotes Comparison
T3178 707-708 . denotes .
T3177 692-693 CD denotes 1
T3176 691-692 : denotes :
T3175 694-707 NN denotes acylcarnitine
T3174 688-691 NN denotes C10
T3173 681-683 PRP denotes it
T3172 675-680 NN denotes mouse
T3171 671-674 DT denotes the
T3170 668-670 IN denotes in
T3169 684-687 VBD denotes was
T3168 660-667 IN denotes whereas
T3167 658-660 , denotes ,
T3166 652-658 NNS denotes humans
T3165 649-651 IN denotes in
T3164 635-648 NN denotes acylcarnitine
T3163 632-634 NN denotes C8
T3162 611-622 JJ denotes predominant
T3161 623-627 NN denotes peak
T3160 607-610 DT denotes the
T3159 605-607 , denotes ,
T3158 598-605 RB denotes however
T3157 596-597 : denotes ;
T3156 585-591 NN denotes mutant
T3155 592-596 NNS denotes mice
T3154 581-584 DT denotes the
T3153 577-580 VBD denotes did
T3152 574-576 IN denotes as
T3151 572-574 , denotes ,
T3150 558-572 NNS denotes acylcarnitines
T3149 556-557 CD denotes 1
T3148 555-556 : denotes :
T3147 552-555 NN denotes C10
T3146 548-551 CC denotes and
T3145 546-548 , denotes ,
T3144 544-546 NN denotes C8
T3143 542-544 , denotes ,
T3142 540-542 NN denotes C6
T3141 537-539 IN denotes of
T3140 530-536 NNS denotes levels
T3139 521-529 VBN denotes elevated
T3138 516-520 IN denotes with
T3137 628-631 VBD denotes was
T3136 508-515 VBP denotes present
T3135 499-507 NNS denotes patients
T3134 493-498 JJ denotes Human
T3133 492-708 sentence denotes Human patients present with elevated levels of C6, C8, and C10:1 acylcarnitines, as did the mutant mice; however, the predominant peak was C8 acylcarnitine in humans, whereas in the mouse it was C10:1 acylcarnitine.
T3132 491-492 . denotes .
T3131 490-491 -RRB- denotes )
T3130 488-490 CD denotes 4C
T3129 481-487 NN denotes Figure
T3128 480-481 -LRB- denotes (
T3127 460-461 HYPH denotes -
T3126 461-470 JJ denotes deficient
T3125 456-460 NN denotes MCAD
T3124 471-479 NNS denotes patients
T3123 450-455 JJ denotes human
T3122 447-449 IN denotes of
T3121 441-446 DT denotes those
T3120 436-440 IN denotes from
T3119 426-435 JJ denotes different
T3118 415-416 SYM denotes −
T3117 414-415 HYPH denotes /
T3116 413-414 SYM denotes −
T3115 409-413 NN denotes MCAD
T3114 417-421 NNS denotes mice
T3113 405-408 DT denotes the
T3112 402-404 IN denotes of
T3111 379-392 NN denotes acylcarnitine
T3110 393-401 NNS denotes profiles
T3109 375-378 DT denotes the
T3108 373-375 , denotes ,
T3107 422-425 VBP denotes are
T3106 366-373 RB denotes However
T3105 365-492 sentence denotes However, the acylcarnitine profiles of the MCAD−/− mice are different from those of human MCAD-deficient patients (Figure 4C).
T3104 364-365 . denotes .
T3103 363-364 -RRB- denotes )
T3102 361-363 CD denotes 4B
T3101 354-360 NN denotes Figure
T3100 353-354 -LRB- denotes (
T3099 347-352 NN denotes serum
T3098 344-346 IN denotes in
T3097 341-343 IN denotes as
T3096 319-332 NN denotes acylcarnitine
T3095 311-318 JJ denotes similar
T3094 333-340 NN denotes pattern
T3093 309-310 DT denotes a
T3092 300-308 VBD denotes revealed
T3091 291-299 NN denotes analysis
T3090 277-290 NN denotes acylcarnitine
T3089 272-276 NN denotes Bile
T3088 271-365 sentence denotes Bile acylcarnitine analysis revealed a similar acylcarnitine pattern as in serum (Figure 4B).
T3087 270-271 . denotes .
T3086 269-270 -RRB- denotes )
T3085 267-269 CD denotes 4A
T3084 260-266 NN denotes Figure
T3083 259-260 -LRB- denotes (
T3082 237-250 NN denotes acylcarnitine
T3081 251-258 NN denotes profile
T3080 233-236 DT denotes the
T3079 230-232 IN denotes in
R1921 T3027 T3028 nsubj Comparison,revealed
R1922 T3029 T3027 prep of,Comparison
R1923 T3030 T3031 nmod MCAD,mice
R1924 T3031 T3029 pobj mice,of
R1925 T3032 T3030 punct +,MCAD
R1926 T3033 T3030 punct /,MCAD
R1927 T3034 T3030 punct +,MCAD
R1928 T3035 T3030 cc and,MCAD
R1929 T3036 T3030 conj MCAD,MCAD
R1930 T3037 T3036 punct −,MCAD
R1931 T3038 T3036 punct /,MCAD
R1932 T3039 T3036 punct −,MCAD
R1933 T3040 T3041 det no,differences
R1934 T3041 T3028 dobj differences,revealed
R1935 T3042 T3041 amod significant,differences
R1936 T3043 T3041 prep in,differences
R1937 T3044 T3045 amod total,concentrations
R1938 T3045 T3043 pobj concentrations,in
R1939 T3046 T3045 compound serum,concentrations
R1940 T3047 T3045 compound carnitine,concentrations
R1941 T3048 T3041 prep between,differences
R1942 T3049 T3050 nmod MCAD,mice
R1943 T3050 T3048 pobj mice,between
R1944 T3051 T3049 punct +,MCAD
R1945 T3052 T3049 punct /,MCAD
R1946 T3053 T3049 punct +,MCAD
R1947 T3054 T3049 cc and,MCAD
R1948 T3055 T3049 conj MCAD,MCAD
R1949 T3056 T3055 punct −,MCAD
R1950 T3057 T3055 punct /,MCAD
R1951 T3058 T3055 punct −,MCAD
R1952 T3059 T3028 punct ", ",revealed
R1953 T3060 T3028 cc but,revealed
R1954 T3061 T3062 nmod MCAD,mice
R1955 T3062 T3066 nsubj mice,had
R1956 T3063 T3061 punct −,MCAD
R1957 T3064 T3061 punct /,MCAD
R1958 T3065 T3061 punct −,MCAD
R1959 T3066 T3028 conj had,revealed
R1960 T3067 T3068 det a,elevation
R1961 T3068 T3075 nsubj elevation,evident
R1962 T3069 T3070 quantmod 5,6
R1963 T3070 T3073 quantmod 6,fold
R1964 T3071 T3070 punct -,6
R1965 T3072 T3070 quantmod to,6
R1966 T3073 T3068 nummod fold,elevation
R1967 T3074 T3073 punct -,fold
R1968 T3075 T3066 ccomp evident,had
R1969 T3076 T3068 prep of,elevation
R1970 T3077 T3078 compound serum,decenoylcarnitine
R1971 T3078 T3076 pobj decenoylcarnitine,of
R1972 T3079 T3075 prep in,evident
R1973 T3080 T3081 det the,profile
R1974 T3081 T3079 pobj profile,in
R1975 T3082 T3081 compound acylcarnitine,profile
R1976 T3083 T3084 punct (,Figure
R1977 T3084 T3066 parataxis Figure,had
R1978 T3085 T3084 nummod 4A,Figure
R1979 T3086 T3084 punct ),Figure
R1980 T3087 T3066 punct .,had
R1981 T3089 T3090 compound Bile,acylcarnitine
R1982 T3090 T3091 compound acylcarnitine,analysis
R1983 T3091 T3092 nsubj analysis,revealed
R1984 T3093 T3094 det a,pattern
R1985 T3094 T3092 dobj pattern,revealed
R1986 T3095 T3094 amod similar,pattern
R1987 T3096 T3094 compound acylcarnitine,pattern
R1988 T3097 T3094 prep as,pattern
R1989 T3098 T3097 prep in,as
R1990 T3099 T3098 pobj serum,in
R1991 T3100 T3101 punct (,Figure
R1992 T3101 T3092 parataxis Figure,revealed
R1993 T3102 T3101 nummod 4B,Figure
R1994 T3103 T3101 punct ),Figure
R1995 T3104 T3092 punct .,revealed
R1996 T3106 T3107 advmod However,are
R1997 T3108 T3107 punct ", ",are
R1998 T3109 T3110 det the,profiles
R1999 T3110 T3107 nsubj profiles,are
R2000 T3111 T3110 compound acylcarnitine,profiles
R2001 T3112 T3110 prep of,profiles
R2002 T3113 T3114 det the,mice
R2003 T3114 T3112 pobj mice,of
R2004 T3115 T3114 nmod MCAD,mice
R2005 T3116 T3115 punct −,MCAD
R2006 T3117 T3115 punct /,MCAD
R2007 T3118 T3115 punct −,MCAD
R2008 T3119 T3107 acomp different,are
R2009 T3120 T3119 prep from,different
R2010 T3121 T3120 pobj those,from
R2011 T3122 T3121 prep of,those
R2012 T3123 T3124 amod human,patients
R2013 T3124 T3122 pobj patients,of
R2014 T3125 T3126 npadvmod MCAD,deficient
R2015 T3126 T3124 amod deficient,patients
R2016 T3127 T3126 punct -,deficient
R2017 T3128 T3129 punct (,Figure
R2018 T3129 T3107 parataxis Figure,are
R2019 T3130 T3129 nummod 4C,Figure
R2020 T3131 T3129 punct ),Figure
R2021 T3132 T3107 punct .,are
R2022 T3134 T3135 amod Human,patients
R2023 T3135 T3136 nsubj patients,present
R2024 T3136 T3137 ccomp present,was
R2025 T3138 T3136 prep with,present
R2026 T3139 T3140 amod elevated,levels
R2027 T3140 T3138 pobj levels,with
R2028 T3141 T3140 prep of,levels
R2029 T3142 T3141 pobj C6,of
R2030 T3143 T3142 punct ", ",C6
R2031 T3144 T3142 conj C8,C6
R2032 T3145 T3144 punct ", ",C8
R2033 T3146 T3144 cc and,C8
R2034 T3147 T3144 conj C10,C8
R2035 T3148 T3147 punct :,C10
R2036 T3149 T3147 nummod 1,C10
R2037 T3150 T3142 appos acylcarnitines,C6
R2038 T3151 T3136 punct ", ",present
R2039 T3152 T3153 mark as,did
R2040 T3153 T3136 advcl did,present
R2041 T3154 T3155 det the,mice
R2042 T3155 T3153 nsubj mice,did
R2043 T3156 T3155 compound mutant,mice
R2044 T3157 T3137 punct ;,was
R2045 T3158 T3137 advmod however,was
R2046 T3159 T3137 punct ", ",was
R2047 T3160 T3161 det the,peak
R2048 T3161 T3137 nsubj peak,was
R2049 T3162 T3161 amod predominant,peak
R2050 T3163 T3164 compound C8,acylcarnitine
R2051 T3164 T3137 attr acylcarnitine,was
R2052 T3165 T3137 prep in,was
R2053 T3166 T3165 pobj humans,in
R2054 T3167 T3137 punct ", ",was
R2055 T3168 T3169 mark whereas,was
R2056 T3169 T3137 advcl was,was
R2057 T3170 T3169 prep in,was
R2058 T3171 T3172 det the,mouse
R2059 T3172 T3170 pobj mouse,in
R2060 T3173 T3169 nsubj it,was
R2061 T3174 T3175 nmod C10,acylcarnitine
R2062 T3175 T3169 attr acylcarnitine,was
R2063 T3176 T3174 punct :,C10
R2064 T3177 T3174 nummod 1,C10
R2065 T3178 T3137 punct .,was

craft-ca-core-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T3218 694-707 CHEBI:17387 denotes acylcarnitine
T3217 675-680 NCBITaxon:10088 denotes mouse
T3216 652-658 NCBITaxon:9606 denotes humans
T3215 635-648 CHEBI:17387 denotes acylcarnitine
T3214 592-596 NCBITaxon:10088 denotes mice
T3213 558-572 CHEBI:17387 denotes acylcarnitines
T3212 493-498 NCBITaxon:9606 denotes Human
T3211 450-455 NCBITaxon:9606 denotes human
T3210 417-421 NCBITaxon:10088 denotes mice
T3209 379-392 CHEBI:17387 denotes acylcarnitine
T3208 347-352 UBERON:0001977 denotes serum
T3207 319-332 CHEBI:17387 denotes acylcarnitine
T3206 277-290 CHEBI:17387 denotes acylcarnitine
T3205 272-276 UBERON:0001970 denotes Bile
T3204 237-250 CHEBI:17387 denotes acylcarnitine
T3203 204-221 CHEBI:86063 denotes decenoylcarnitine
T3202 198-203 UBERON:0001977 denotes serum
T3201 161-165 NCBITaxon:10088 denotes mice
T3200 143-147 NCBITaxon:10088 denotes mice
T3199 90-99 CHEBI:17126 denotes carnitine
T3198 84-89 UBERON:0001977 denotes serum
T3197 34-38 NCBITaxon:10088 denotes mice

craft-ca-core-ex-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T3291 694-707 CHEBI:17387 denotes acylcarnitine
T3290 675-680 NCBITaxon:10088 denotes mouse
T3262 135-139 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3261 129-130 SO_EXT:normal_or_wild_type_or_present denotes +
T3260 127-128 SO_EXT:normal_or_wild_type_or_present denotes +
T3259 123-127 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3258 90-99 CHEBI:17126 denotes carnitine
T3257 84-89 UBERON:0001977 denotes serum
T3256 34-38 NCBITaxon:10088 denotes mice
T3255 32-33 SO_EXT:sequence_nullness_or_absence denotes −
T3254 30-31 SO_EXT:sequence_nullness_or_absence denotes −
T3253 26-30 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3252 20-21 SO_EXT:normal_or_wild_type_or_present denotes +
T3251 18-19 SO_EXT:normal_or_wild_type_or_present denotes +
T3250 14-18 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3289 652-658 NCBITaxon:9606 denotes humans
T3288 635-648 CHEBI:17387 denotes acylcarnitine
T3287 592-596 NCBITaxon:10088 denotes mice
T3286 585-591 SO_EXT:sequence_altered_entity_or_alteration_process denotes mutant
T3285 558-572 CHEBI:17387 denotes acylcarnitines
T3284 493-498 NCBITaxon:9606 denotes Human
T3283 456-460 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3282 450-455 NCBITaxon:9606 denotes human
T3281 417-421 NCBITaxon:10088 denotes mice
T3280 415-416 SO_EXT:sequence_nullness_or_absence denotes −
T3268 159-160 SO_EXT:sequence_nullness_or_absence denotes −
T3267 157-158 SO_EXT:sequence_nullness_or_absence denotes −
T3266 153-157 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3265 143-147 NCBITaxon:10088 denotes mice
T3264 141-142 SO_EXT:sequence_nullness_or_absence denotes −
T3263 139-140 SO_EXT:sequence_nullness_or_absence denotes −
T3279 413-414 SO_EXT:sequence_nullness_or_absence denotes −
T3278 409-413 GO_PR_EXT:medium_chain_acyl_CoA_dehydrogenase denotes MCAD
T3277 379-392 CHEBI:17387 denotes acylcarnitine
T3276 347-352 UBERON:0001977 denotes serum
T3275 319-332 CHEBI:17387 denotes acylcarnitine
T3274 277-290 CHEBI:17387 denotes acylcarnitine
T3273 272-276 UBERON:0001970 denotes Bile
T3272 237-250 CHEBI:17387 denotes acylcarnitine
T3271 204-221 CHEBI:86063 denotes decenoylcarnitine
T3270 198-203 UBERON:0001977 denotes serum
T3269 161-165 NCBITaxon:10088 denotes mice